Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Maintenance in Non-gBRCAm Platinum-Sensitive Relapsed Ovarian Cancer
NCT03402841Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AstraZeneca. Started Jan 2018; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03402841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402841.